DK1447414T3 - Antagonistpeptider af carcinoembronisk antigen (CEA) - Google Patents

Antagonistpeptider af carcinoembronisk antigen (CEA)

Info

Publication number
DK1447414T3
DK1447414T3 DK04011673T DK04011673T DK1447414T3 DK 1447414 T3 DK1447414 T3 DK 1447414T3 DK 04011673 T DK04011673 T DK 04011673T DK 04011673 T DK04011673 T DK 04011673T DK 1447414 T3 DK1447414 T3 DK 1447414T3
Authority
DK
Denmark
Prior art keywords
cea
peptides
carcinoembryonic antigen
antigen antagonist
agonists
Prior art date
Application number
DK04011673T
Other languages
English (en)
Inventor
Jeffrey Schlom
Nee Barzaga Maria Elen Salazar
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1447414T3 publication Critical patent/DK1447414T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK04011673T 1997-10-10 1998-09-22 Antagonistpeptider af carcinoembronisk antigen (CEA) DK1447414T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10
PCT/US1998/019794 WO1999019478A1 (en) 1997-10-10 1998-09-22 Agonist and antagonist peptides of carcinoembryonic antigen (cea)

Publications (1)

Publication Number Publication Date
DK1447414T3 true DK1447414T3 (da) 2007-09-10

Family

ID=22036775

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04011673T DK1447414T3 (da) 1997-10-10 1998-09-22 Antagonistpeptider af carcinoembronisk antigen (CEA)

Country Status (11)

Country Link
EP (1) EP1017810B1 (da)
JP (1) JP4291508B2 (da)
AT (2) ATE267213T1 (da)
AU (1) AU745863B2 (da)
CA (1) CA2308127C (da)
CY (1) CY1107706T1 (da)
DE (2) DE69837896T2 (da)
DK (1) DK1447414T3 (da)
ES (2) ES2217585T3 (da)
PT (1) PT1447414E (da)
WO (1) WO1999019478A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
EP2169073B1 (en) * 1999-10-11 2013-11-13 Institut Pasteur Vector for the preparation of immunotherapeutical compositions
AU1013601A (en) * 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
JP2004524004A (ja) * 2000-07-31 2004-08-12 アヴェンティス パストゥール リミテッド 修飾ｃｅａおよびその使用
AU2003203140A1 (en) * 2002-01-17 2003-07-30 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
WO2004050855A2 (en) * 2002-12-04 2004-06-17 Baylor Research Institute Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
KR101241272B1 (ko) * 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
WO2005114444A1 (en) 2004-04-30 2005-12-01 America Online, Inc. Network configuration management
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
BRPI0814140A2 (pt) 2007-07-27 2017-03-28 Immatics Biotechnologies Gmbh composição de peptídeos associados a tumor e vacina anticâncer relacionada
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
KR20170102002A (ko) 2015-01-09 2017-09-06 이투빅스 코포레이션 에볼라 바이러스 백신접종을 위한 방법 및 조성물
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102623C (en) * 1991-05-06 2003-04-22 Jeffrey Schlom Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
EP1017810A1 (en) 2000-07-12
PT1447414E (pt) 2007-07-18
CA2308127A1 (en) 1999-04-22
ES2217585T3 (es) 2004-11-01
ES2286530T3 (es) 2007-12-01
AU745863B2 (en) 2002-04-11
JP4291508B2 (ja) 2009-07-08
AU9500498A (en) 1999-05-03
WO1999019478A1 (en) 1999-04-22
JP2002500002A (ja) 2002-01-08
DE69837896D1 (de) 2007-07-19
DE69824023D1 (de) 2004-06-24
CY1107706T1 (el) 2013-04-18
ATE364048T1 (de) 2007-06-15
ATE267213T1 (de) 2004-06-15
CA2308127C (en) 2011-03-22
DE69837896T2 (de) 2008-02-14
DE69824023T2 (de) 2005-05-12
EP1017810B1 (en) 2004-05-19

Similar Documents

Publication Publication Date Title
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
ATE272070T1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
DE69533923D1 (de) Cytokinin-designiertes lerk-5
ATE247484T1 (de) Von der telomerase abgeleitete antigene peptide
GEP20074091B (en) Cripto blocking antibodies and uses thereof
PT1066380E (pt) Receptor de celula t soluvel
TR200003843T2 (tr) HCV kaplama proteinlerinin parçacıkları: aşılama için kullanım
ATE217795T1 (de) Saponin-antigen-konjugate und ihre verwendung
GEP20105118B (en) Anti-vegf antibodies
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
GB9103974D0 (en) Therapeutically useful peptides or peptide fragments
PT1171143E (pt) Extracto peptidico de tremoco e composicao farmaceutica ou cosmetica ou nutraceutica compreendendo o referido extracto
CR8231A (es) Anticuerpos rg1 y uso de los mismos
IL142905A0 (en) Functional antagonists of hedgehog activity
FI933253A7 (fi) Uusia amyliiniantagonistipeptidejä ja käyttö amyliiniantagonisteina
IL145689A0 (en) Methods
HU9300900D0 (en) Human gamma-interferon antagonists
EP1447414A3 (en) Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
AU2002302751A1 (en) Dimerized t-cell receptor fragment, its compositions and use
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
EP1578772A4 (en) CYTOKINS AND CYTOKIN RECEPTORS WITH REDUCED IMMUNOGENICITY
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt
DE60045776D1 (de) Hla-bindungspeptide und ihre anwendungszwecke
ES2194008T3 (es) Proteina p100 del virus del herpes humano tipo 6, las correspondientes secuencias de adn, su preparacion y uso.